As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

and build our commercial business," said Bancel. In the near term, that means driving uptake of Moderna's Spikevax COVID-19 vaccines and recently-approved mResvia for respiratory syncytial virus ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

The virus was confirmed on Friday at a commercial poultry production facility ... also been confirmed in dozens of dairy farms. In 2023, Moderna commenced a Phase 1/2 study to generate safety ...

The pandemic accelerated Moderna's evolution into a commercial-stage biotech, and we expect that the firm's ramp-up in manufacturing and clinical know-how will pave the way for faster timelines ...

Shares plunge more than 24% in early trading 2025 revenue forecast misses expectations, prior view CEO Bancel says to reduce 2025 cash costs by $1 bln Jan 13 (Reuters) - Moderna (MRNA.O), opens ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Moderna (NASDAQ: MRNA ... That seems like a very reasonable price when you consider commercial-stage biotech stocks tend to trade for mid-single-digit multiples of trailing-12-month sales.

This diverse pipeline exemplifies Moderna's road map to extend its mRNA technology into new categories, positioning itself as a more diversified and mature commercial-stage biotech company.

it is clear that the past year brought formidable challenges for Moderna along with significant advances, particularly for our development pipeline. It was a year of navigating a dynamic global ...